Longevity, built around you.Licensed US clinicians·Third-party tested
The Canon

The go-to library for everything peptide.

The best of the open web on peptides, the papers, lectures, registries, and researchers we'd send a smart friend to. Vetted, dated, re-checked. Authoritative sources only: never a vendor, never a grey-market seller, never a dosing how-to.

32 references5 kindsWe link, we don't endorse
TypeGoal32 references
We link, we don't endorse. Peptós.LIFE curates these as educational references. A link is not an endorsement of any product, protocol, or dose, and never an instruction to self-administer. Compounded peptides are not FDA-approved, and a favorable advisory-committee vote is a recommendation, not FDA approval or authorization to compound.

Read

Primary literature + high-quality explainer journalism.
ReadVerified Jul 30, 2026FDA advisory committee backs BPC-157 and KPV (regulatory-trade report)The clearest regulatory-trade account of Day 1, reporting the 8–6–1 vote to recommend BPC-157 and KPV, and why the panel broke with FDA scientists. Published mid-session: TB-500 was still under discussion and MOTS-c had not yet been voted. A recommendation, not authorization to compound.Regulatory Focus · RAPS · Joanne S. Eglovitch · Regulatory Affairs Professionals SocietyReadVerified Jul 24, 2026FDA advisers vote to ease regulation of popular peptidesPlain-English national coverage of the panel's decision to recommend easier access, with the context on why FDA scientists disagreed. A committee recommendation is not FDA approval or availability.NPR · NPR Health / Shots · National Public RadioReadVerified Jul 31, 2026What the six recommended peptides are, and what happens nextThe clearest account of what still has to happen: the FDA must formally adopt the recommendations, then run notice-and-comment rulemaking, and only a final rule in the Federal Register actually adds a peptide to the Bulks List. Collects every Day-1 and Day-2 tally in one place and quotes the committee's own dissent on how thin the human evidence is. A recommendation, not approval, and not availability.CNN · CNN Health · Cable News NetworkReadVerified Jul 24, 2026BPC-157 cytoprotection & tissue-repair literature (review set)The core body of preclinical work behind nearly every BPC-157 claim, overwhelmingly animal models, which is exactly why we grade it D.Journal of Physiology & Pharmacology · PubMed · Sikirić P, et al.ReadVerified Jul 24, 2026Thymosin β4 in tissue repair (the molecule TB-500 fragments)The legitimate science is on full-length thymosin β4, useful for seeing how far the marketed 'TB-500' fragment sits from trial-grade material.Annals of the NY Academy of Sciences · PubMed · Goldstein AL, et al.ReadVerified Jul 24, 2026GHK-Cu: regenerative & skin-remodeling actions (review)The foundational copper-peptide review. Note it concerns topical/cosmetic and cell-culture work, not the injectable claims we keep separate.Int. J. Molecular Sciences · PubMed · Pickart L, Margolina AReadVerified Aug 11, 2026Peptide supplements in sports medicine: what the human evidence shows (scoping review)An independent PRISMA scoping review of BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu for musculoskeletal recovery. Two thirds of the published work is preclinical animal modelling, the human studies are a handful and mostly lack rigorous controls, and route and dosing vary widely across them. The authors conclude the claimed benefits are unsubstantiated by current human trials and that these peptides should not be recommended as a replacement or adjunct for standard orthopaedic care. It grades the evidence, which moves independently of the regulatory question: a favorable advisory vote says nothing about how good the science is.The American Journal of Sports Medicine · PubMed · Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ · Dept. of Orthopaedic Surgery, David Geffen School of Medicine at UCLAReadVerified Jul 24, 2026NAD+ metabolism in ageing & disease (review)The serious mechanistic review of NAD+ biology, and a clear-eyed account of how early the human longevity evidence still is.Nature Reviews Mol. Cell Biology · PubMed · Covarrubias AJ, Verdin E, et al.ReadVerified Jul 24, 2026Sermorelin & GHRH-analog clinical literatureThe clinical record behind the legal GH-axis answer, including its FDA-labeling history as the discontinued drug Geref.PubMed · Multiple investigatorsReadVerified Jul 24, 2026Tesamorelin pivotal trials (FDA-approved GHRH analog)The strongest evidence pedigree in the GH-axis group, randomized human trials behind the approved product (Egrifta).New England Journal of Medicine · PubMed · Falutz J, et al.ReadVerified Jul 24, 2026Bremelanotide (PT-141) phase-3 trials for desireThe randomized human evidence behind PT-141, the rare research-peptide story with an FDA-approved counterpart (Vyleesi).Obstetrics & Gynecology · PubMed · Clayton AH, et al.ReadVerified Jul 24, 2026MOTS-c: a mitochondrial-derived regulator of metabolismThe foundational MOTS-c biology. Fascinating mechanism, almost entirely preclinical, the basis for its grade-D, waitlist position.Cell Metabolism · PubMed · Lee C, et al.ReadVerified Jul 24, 2026Epitalon / pineal-peptide regulation studiesThe original (older, methodologically limited) work behind epitalon's bold longevity folklore, read it to see where the claims outrun the data.PubMed · Khavinson VK, et al.ReadVerified Jul 24, 2026KPV, the anti-inflammatory α-MSH tripeptide (literature)The preclinical inflammation and gut-barrier literature behind KPV, mostly cell and animal models, which is why we grade it D and keep it education-only.PubMed · Multiple investigatorsReadVerified Jul 24, 2026Delta sleep-inducing peptide (DSIP / emideltide) researchThe older, thin human record behind DSIP's sleep and stress claims, useful for seeing how far the folklore runs ahead of the trial data.PubMed · Multiple investigatorsReadVerified Jul 24, 2026Semax, a synthetic ACTH(4–10) analog (literature)The mostly preclinical and Russian-language evidence base behind Semax's nootropic and neuroprotective claims, limited controlled human data, which is why we grade it C.PubMed · Multiple investigatorsReadVerified Jul 24, 2026Semaglutide weight-management trials (STEP program)Grade-A human evidence, large randomized trials. The honest contrast with the research peptides everyone lumps in with 'peptides.'NEJM / JAMA · PubMed · Wilding JPH, et al.ReadVerified Jul 24, 2026Tirzepatide weight & metabolic trials (SURMOUNT / SURPASS)The strongest efficacy data in the category, from randomized human trials, the evidence bar everything else is measured against.NEJM · PubMed · Jastreboff AM, et al.ReadVerified Jul 24, 2026Rapamycin, mTOR, and lifespan (review set)The mechanistic and animal-lifespan evidence behind rapamycin, strong across model organisms, still early in humans, which is exactly why we grade it B and gate it behind a clinician.Nature / Science of Aging · PubMed · Multiple investigatorsReadVerified Jul 24, 2026Metformin and the TAME trial (Targeting Aging with Metformin)The framing behind metformin's longevity hypothesis and the trial designed to test it, the honest line between 'proven for diabetes' and 'still being tested for aging.'PubMed · Cell Metabolism · Barzilai N, et al.

Watch

Authoritative video explainers, lectures, credentialed interviews.
WatchVerified Jul 24, 2026Huberman Lab, peptides for health, performance & longevityA long-form, mechanism-level overview from a credentialed academic host. Useful framing; we still hold its claims to our own evidence grades.Huberman Lab · Andrew Huberman, PhD · Neuroscientist · Stanford School of Medicine

Listen

Vetted audio, credentialed-host science podcasts.
ListenVerified Jul 24, 2026The Peter Attia Drive, peptides & longevity therapeuticsA practicing physician's skeptical, evidence-first walk through the longevity compounds, strong on separating mechanism from marketing.The Drive · Peter Attia, MD · Physician · longevity medicine

Reference

Authoritative databases, registries, and regulatory tools.
ReferenceVerified Jul 27, 2026FDA Pharmacy Compounding Advisory CommitteeThe standing committee that recommends which peptides may be compounded under §503A. Across July 23–24, 2026 it recommended six of seven: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, and declined Emideltide/DSIP. A recommendation is advisory, FDA rulemaking must still act on it before anything can be compounded.U.S. Food & Drug Administration · FDA / CDERReferenceVerified Jul 24, 2026503A Bulk Drug Substances, nominations & statusThe actual list that governs what a 503A pharmacy can legally compound. The difference between “removed from Category 2” and “eligible” lives here.U.S. Food & Drug Administration · FDAReferenceVerified Jul 24, 2026Federal Register, drug-compounding docketsWhere rulemaking actually happens. A favorable PCAC vote is advisory, the binding step is a rule published here.Office of the Federal Register · U.S. GovernmentReferenceVerified Aug 10, 2026FDA PCAC meeting page, July 23–24, 2026 peptide reviewFDA's page for the two-day meeting, carrying the agency's pre-meeting materials for all seven peptides: briefing documents, the final agenda and roster, and the questions put to the committee, which set out fourteen separate votes, a free-base and an acetate form for each substance. The page still carries no minutes, transcript or official vote tallies, so the official record of the vote remains unpublished. The committee recommended six of seven, per trade reporting, with Emideltide/DSIP the only rejection. Advisory: it leads to rulemaking, not approval or availability.U.S. Food & Drug Administration · FDA / CDERReferenceVerified Jul 24, 2026WADA Prohibited ListThe authoritative source on whether a compound is banned in sport. Several recovery and GH-axis peptides are prohibited, this is how a tested athlete checks.World Anti-Doping Agency · WADAReferenceVerified Jul 24, 2026ClinicalTrials.gov, registry of human studiesSearch any compound to see what is actually being tested in humans, by whom, and at what phase, the antidote to anecdote.U.S. National Library of Medicine · NIH / NLMReferenceVerified Jul 24, 2026PubMed, the primary-literature indexThe front door to the peer-reviewed evidence base. Every grade on this site is anchored to what is (and isn't) indexed here.U.S. National Library of Medicine · NIH / NCBIReferenceVerified Jul 24, 2026MedlinePlus, plain-language drug & supplement factsGovernment-run, plain-English reference for approved drugs and common supplements, a neutral second opinion to anything you read here.U.S. National Library of Medicine · NIH

People

Named researchers and clinicians with a real public track record.
PeopleVerified Jul 24, 2026Predrag Sikirić, the primary BPC-157 investigatorRead the source, not the summary: the researcher whose lab produced most of the BPC-157 evidence. Note how little of it is human.PubMed author profile · Predrag Sikirić, MD, PhD · University of Zagreb · pharmacologyPeopleVerified Jul 24, 2026Eric Verdin, NAD+ & ageing biologyA leading academic voice on NAD+, useful counterweight to the supplement industry's lifespan claims.Buck Institute for Research on Aging · Eric Verdin, MD · President & CEO, Buck Institute
Back to the Knowledge Base
Honest by design. Nothing oversold.
Third-Party
Batch Tested
US-Licensed
Clinicians
Live FDA
Peptide Tracker